Can targeting lipid metabolism enzymes be a therapeutic strategy in cancer?
Yes, targeting lipid metabolism enzymes can be a promising therapeutic strategy in cancer. By inhibiting key enzymes such as FASN, ACC, SREBPs, LPL, and CPT1, it is possible to disrupt the lipid metabolic pathways that cancer cells depend on. This can lead to reduced tumor growth, increased cancer cell death, and enhanced sensitivity to existing treatments. Several inhibitors targeting these enzymes are currently under investigation in preclinical and clinical studies.
